Get the Stockscreener App
1.68
1.75%
-0.03
After Hours:
1.72
0.04
+2.38%
NanoViricides Inc stock is traded at $1.68, with a volume of 170.24K.
It is down -1.75% in the last 24 hours and up +20.00% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.71
Open:
$1.72
24h Volume:
170.24K
Relative Volume:
0.75
Market Cap:
$27.00M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-2.40
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+0.00%
1M Performance:
+20.00%
6M Performance:
+51.35%
1Y Performance:
-23.64%
1-Day Range:
$1.65
$1.75
1-Week Range:
$1.54
$1.78
52-Week Range:
$0.94
$2.3499
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.68 | 27.48M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
What catalysts could drive NanoViricides Inc. stock higher in 2025Achieve superior capital gains with smart trades - jammulinksnews.com
When is NanoViricides Inc. stock expected to show significant growthFree Wealth Management Insights - jammulinksnews.com
How volatile is NanoViricides Inc. stock compared to the marketBuild a winning investment strategy today - jammulinksnews.com
Is NanoViricides Inc. Stock a Smart Buy in 2025 Investment Analysis InsideHigh Accuracy Alerts - Newser
What makes NanoViricides Inc. stock price move sharplyMassive Gain Ideas - Newser
Key External Factors That Drive NanoViricides Inc. Stock Price MovementsInsider Strategy Insight - Newser
What markets is NanoViricides Inc. expanding into Is NVST stock a good long term investment optionBuild a portfolio that delivers consistent profits - jammulinksnews.com
Why NanoViricides Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Metal.it
What drives NanoViricides Inc. stock priceConsistently outstanding ROI - Autocar Professional
What analysts say about NanoViricides Inc. stockExtraordinary earning power - Autocar Professional
Is NanoViricides Inc. a good long term investmentFree Trend-Following Techniques - Autocar Professional
Is NanoViricides Inc. stock a growth or value playFree Stock Chart Pattern Guide - jammulinksnews.com
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value - Greenville Online
About Us - FinancialContent
NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387 - Proactive financial news
NanoViricides (NNVC) Highlights Potential of Antiviral Drug NV-3 - GuruFocus
Multi-Billion Dollar Opportunity: NanoViricides' New Drug Fights COVID, Flu, RSV and Measles with Single Treatment - Stock Titan
NanoViricides Inc. Stock Analysis and ForecastHigh-octane gains - jammulinksnews.com
How NanoViricides Inc. stock performs during market volatilityFree Consultation - Newser
Measles Now Has a DrugNV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides - Lohud
NanoViricides says lead antiviral boosted survival in measles-infected mice - Proactive financial news
Breakthrough: New Drug NV-387 Could Be First-Ever Treatment for Measles as Global Cases Surge - Stock Titan
Mpox Antiviral Clinical Trial Advances as WHO Extends Global Emergency - Global Biodefense
WHO Extended Global Emergency Status of MPox EpidemicDevelopment of Treatment for MPox with NV-387 is Timely, Says NanoViricides - Pocono Record
NanoViricides Advances MPox Treatment Development Amid WHO's Extended Health Emergency - citybuzz -
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):